Biren Saraiya

Rutgers, The State University of New Jersey

Also affiliated with Maimonides Medical Center, Rutgers Cancer Institute

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 7%percentile

0.104Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Factors associated with clinical trial participation for patients with renal cell carcinoma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.670

Top 78%

0.104DataRank

Top 78%1 citations

Sinae Kim, Arnav Srivastava, Hiren V. Patel, Tina Mayer, Biren Saraiya +2 more

Papers

Driven by 18 papers — median percentile 0. Top paper: “Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors”.

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Journal of Clinical Oncology(2020)10.1200/jco.20.01652

N/A

3.5DataRank · unranked

138 citations

Rosa Nadal, Daniel M. Girardi, Scot A. Niglio, Lisa Ley, Lisa M. Cordes +30 more

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3726

N/A

1.1DataRank · unranked

24 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo Lara, Sumanta K. Pal +30 more

Project HERO: a randomized trial of Tai Chi qigong versus intensity-matched exercise and usual care for fatigue in older male cancer survivors

BMC Complementary Medicine and Therapies(2025)10.1186/s12906-025-04988-7

N/A

0.104DataRank · unranked

1 citations

Jinghua An, Yong Lin, Samuel Tundealao, Biren Saraiya, Shou‐En Lu +12 more

Factors associated with clinical trial participation for patients with renal cell carcinoma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.670

Top 78%

0.104DataRank

Top 78%1 citations

Sinae Kim, Arnav Srivastava, Hiren V. Patel, Tina Mayer, Biren Saraiya +2 more

Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.3

N/A

0DataRank · unranked

9 citations

Daniel M. Girardi, Scot A. Niglio, Rosa Maria Nadal, Lisa M. Cordes, Seth M. Steinberg +15 more

Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.283

N/A

0DataRank · unranked

6 citations

Hiren V. Patel, Sinae Kim, Brian Shinder, Joshua Sterling, Alexandra L. Tabakin +9 more

Factors associated with palliative care (PC) utilization in advanced and metastatic renal cell carcinoma (RCC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.297

N/A

0DataRank · unranked

3 citations

Joshua Sterling, Arnav Srivastava, Sinae Kim, Biren Saraiya, Tina Mayer +3 more

Factors associated with palliative care utilization in advanced and metastatic renal cell carcinoma.

Journal of Clinical Oncology(2021)10.1200/jco.2020.39.28_suppl.146

N/A

0DataRank · unranked

1 citations

Joshua Sterling, Arnav Srivastava, Sinae Kim, Biren Saraiya, Tina Mayer +5 more

Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5039

N/A

0DataRank · unranked

3 citations

Daniel M. Girardi, Amir Mortazavi, Primo N. Lara, Sumanta K. Pal, Biren Saraiya +15 more

A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5110

N/A

0DataRank · unranked

2 citations

Wanling Xie, Archana Ajmera, Arlene Araneta, Christina Jamieson, Edmund Folefac +14 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.22486571

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Figshare(2023)10.1158/1078-0432.22486556.v1

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Data from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.c.6532346.v1

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Final results from a phase 1 trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced/metastatic genitourinary tumors

Research Square(2023)10.21203/rs.3.rs-2924051/v1

N/A

0DataRank · unranked

0 citations

Scot A. Niglio, Rosa Nadal, Andre R. Kydd, Nicholas I. Simon, Lisa Ley +36 more

Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate Cancer

Advances in Radiation Oncology(2024)10.1016/j.adro.2024.101507

N/A

0DataRank · unranked

7 citations

Matthew P. Deek, Rebecca A. Deek, Ozan Cem Güler, Pervin Hürmüz, Mehmet Reyhan +22 more

Factors associated with clinical trial participation for patients with prostate cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.29_suppl.96

N/A

0DataRank · unranked

3 citations

Sinae Kim, Hiren V. Patel, Arnav Srivastava, Tina Mayer, Biren Saraiya +2 more

Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy

European Urology Oncology(2025)10.1016/j.euo.2025.07.007

N/A

0DataRank · unranked

0 citations

Kim Van der Eecken, Yang Song, Amol C. Shetty, Elai Davicioni, James A. Proudfoot +28 more

Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5037

N/A

0DataRank · unranked

2 citations

Scot A. Niglio, Amir Mortazavi, Primo Lara, Sumanta K. Pal, Biren Saraiya +15 more

Biren Saraiya

Indexed papers

Top data-sharing exemplar

Papers